Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974267 | 0.97 | LTA4H (0.33) | LATS1LTA4HL3MBTL1LIPGMAPT | |
| SCHEMBL973646 | 0.85 | CA12 (0.43) | L3MBTL1CA1CA2 | |
| SCHEMBL9987433 | 0.83 | LTA4H (0.35) | LTA4HCA1CA2 | |
| SCHEMBL970361 | 0.83 | PTPN1 (0.32) | LATS1L3MBTL1MAPT | |
| SCHEMBL9988112 | 0.81 | LTA4H (0.36) | LTA4HCA1CA2 | |
| SCHEMBL973566 | 0.79 | CA1 (0.42) | LTA4HMAPTCA1CA2 | |
| SCHEMBL972865 | 0.77 | GBA1 (0.39) | — | |
| SCHEMBL973499 | 0.76 | LATS1 (0.35) | LATS1 | |
| SCHEMBL9987340 | 0.72 | LMNA (0.44) | L3MBTL1MAPT | |
| SCHEMBL969683 | 0.72 | PIK3CD (0.39) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8178689-B2 | Tricyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | SARABU RAMAKANTH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | LATS1 1737/4885LTA4H 1865/4885L3MBTL1 4254/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | LATS1 1154/4885LTA4H 3974/4885L3MBTL1 4431/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | LATS1 1737/4885LTA4H 1865/4885L3MBTL1 4254/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | LATS1 1823/4885LTA4H 2461/4885L3MBTL1 4364/4885 |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | GPR119, PC, GOT2 | LATS1 3061/4885LTA4H 1046/4885L3MBTL1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.